Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

From sweeping curves to industrial structures, visionary architects have reimagined museums as more than just spaces to view ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...

Here is the full schedule for MLB games on FOX this season with key dates and broadcast information: All games will be ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Itineraries calling at lesser-visited ports, offering off-the-beaten-track experiences, can help pique clients’ interest in ...

One of three men on trial in the case of the purloined potty was involved in stealing it and the other two helped to sell the ...